Limb-Girdle Muscular Dystrophy (LGMD)

Definition

Limb-Girdle Muscular Dystrophy (LGMD) refers to a group of genetic disorders characterized by progressive weakness and wasting of the muscles primarily around the hips and shoulders (the limb-girdle area). It affects voluntary muscles used for movement, leading to difficulties with walking, climbing stairs, lifting, and other activities.

Symptoms

• Progressive muscle weakness starting in the hips and shoulders

• Difficulty walking, running, climbing stairs

• Wasting (atrophy) of muscles in the upper arms, thighs, and pelvic area

• Muscle cramps or pain in some cases

• Difficulty lifting arms or raising objects

• Sometimes cardiac (heart) involvement or respiratory muscle weakness

• Fatigue and loss of endurance

Types of LGMD

LGMD is classified based on inheritance pattern and specific genetic mutations:

1. LGMD Type 1 (Dominant inheritance)

   • Rare

   • Examples: LGMD1A, 1B, etc.

2. LGMD Type 2 (Recessive inheritance)

   • More common

   • Includes many subtypes based on affected genes, such as:

     • LGMD2A (calpainopathy)

     • LGMD2B (dysferlinopathy)

     • LGMD2C to 2L (sarcoglycanopathies, and others)

Each subtype involves mutations in different genes coding for proteins important in muscle function and structure.

Causes

• Genetic mutations in various genes responsible for muscle cell stability, repair, and function.

• Inherited in either an autosomal dominant or autosomal recessive manner depending on the subtype.

Diagnosis

• Clinical evaluation of muscle weakness and pattern

• Family history assessment

• Blood tests showing elevated creatine kinase (CK) levels

• Muscle biopsy showing dystrophic changes

• Genetic testing for specific gene mutations

• Electromyography (EMG) and MRI of muscles may assist diagnosis

Treatment

Currently, there is no cure for LGMD, but management focuses on:

• Physical therapy to maintain muscle strength and flexibility

• Occupational therapy to improve daily functioning

• Use of assistive devices (walkers, wheelchairs) as needed

• Monitoring and managing cardiac and respiratory complications

• Medications for symptom relief (e.g., pain management)

• Emerging gene therapies and research in clinical trials

Prognosis

• Disease progression varies widely depending on the subtype.

• Some forms progress slowly over decades; others may lead to significant disability faster.

• Heart and respiratory complications may impact life expectancy.